Shire on the hunt for right-size deals; AbbVie wins FDA nod for another hep C combo;

@FierceBiotech: Biogen targets new biotech deals after reporting sour numbers, R&D setbacks. More | Follow @FierceBiotech

@JohnCFierce: These days, when the FDA locks the door to a cancer drug, it's saying something -- $SNSS. Release | Follow @JohnCFierce

> Shire ($SHPG), like many drugmakers, has had to pump the brakes on its M&A ambitions in response to rising valuations, but CEO Flemming Ornskov said the company is prepared to wait for the right opportunity. News

> The FDA approved AbbVie's ($ABBV) Technivie, which contains the same active ingredients as the hepatitis C cocktail Viekira Pak, to treat patients with genotype 4 of the virus. More

> Roche's ($RHHBY) to move into Phase III with AC Immune's in-development Alzheimer's treatment paves the way for the Swiss biotech to go public, according to its CEO. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Bard hit with FDA warning letter affecting its vena cava filters. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Stroke-fighting Watchman, SpyGlass endoscope fuel strong Q2 for Boston Sci. Article | Follow @VarunSaxena2

@EmilyWFierce: Spotlight-savvy Kim Kardashian adds Duchesnay med to her talking points. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Wall Street not anticipating another suitor for Thoratec on heels of St. Jude's $3.4B bid. Story

> Stryker: M&A still top priority for cash, but spent only $92M in first half on acquisitions. More

> ViewRay goes public via reverse merger, raises almost $77M since IPO cancellation. Article

> Oxford Performance Materials gets FDA nod for 3-D printed spinal implant. Report

Pharma News

@FiercePharma: India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Two Sandoz plants in Germany and 1 in India to be shuttered by Novartis next year. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Forecast-beating Valeant ups 2015 guidance with fast-growing Xifaxan in mind. Story | Follow @CarlyHFierce

> Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast. More

> Shire CEO: We're prepared to wait for the right deal. Story

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.